Diphencyprone - RXi Pharmaceuticals

Drug Profile

Diphencyprone - RXi Pharmaceuticals

Alternative Names: Diphenylcyclopropenone; Samcyprone

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hapten Pharmaceuticals
  • Developer Hapten Pharmaceuticals; RXi Pharmaceuticals
  • Class Allergens; Antiallergics; Cyclopropanes; Haptens; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia areata; Cancer metastases; Warts

Most Recent Events

  • 14 Sep 2017 Chemical structure information added
  • 06 Sep 2017 RXi Pharmaceuticals completes enrolment in its phase IIa trial for Warts in USA (Topical)
  • 06 Apr 2017 Diphencyprone is still in phase II trials for Warts, Alopecia areata, and Cutaneous metastases of malignant melanoma in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top